Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome (34-DAP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01373333 |
Recruitment Status
:
No longer available
First Posted
: June 14, 2011
Last Update Posted
: July 20, 2016
|
Sponsor:
The Cleveland Clinic
Information provided by (Responsible Party):
The Cleveland Clinic
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | No longer available |
---|---|
Estimated Primary Completion Date : | September 2012 |
Study Completion Date : | No date given |